Manufacturing will mostly take place at Bachem’s new facility that is currently being built in Bubendorf, Switzerland, and due to open in 2024. The order covers a five-year period running from 2027 to 2031.

“Bachem is making a major contribution to supplying the pharmaceutical and biotechnology industries with complex active ingredients for medicines. I am pleased that with this new and important development and supply agreement, we can further diversify our portfolio of long-term customer projects,” said CEO Thomas Meier.

The agreement is the latest in a series of contracts secured since last September. In December, Bachem signed an order to deliver peptide volumes worth a minimum of 1 billion Swiss francs for the period 2025 to 2029.

Two first contracts were signed in September 2022, worth 25 million and 150 million Swiss francs for 2023 and 2024 respectively.

Last October, Bachem revealed it had purchased some land in Eiken, which will be its third site in Switzerland. The company is also expanding capacity in Vionnaz, Switzerland, in the US at Torrance and Vista in California, and at St. Helens in the UK.

Author: Elaine Burridge, Freelance Journalist